Akèy › Kansè Poumon ki pa ti selil › Kalifòni › Orange
Etid klinik pou Kansè Poumon ki pa ti selil nan Orange, CA
25 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote Orange (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
Ap rekriteFaz 2/3
- Providence St. Joseph Hospital, Orange
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Ap rekriteFaz 3
- University of California, Irvine Health, Orange
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Ap rekriteFaz 2
- University of California Irvine, Orange
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Ap rekriteFaz 3
- St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 4002), Orange
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- St. Joseph Hospital Center for Cancer Prevention and Treatment, Orange
- University of California Irvine, Orange
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- University of California, Irvine (UCI) Health - UC Irvine Medical Center, Orange
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 1
- University of California - Irvine, Orange
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Ap rekriteFaz 2/3
- University of California, Irvine (UCI) Health - UC Irvine Medical Center, Orange
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Ap rekriteFaz 1/2
- UC IRVINE Health, Orange
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Ap rekriteFaz 1
- University of California Irvine Medical Center, Orange
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Ap rekriteFaz 3
- Clinical Study Site, Orange
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Ap rekriteFaz 3
- University of California Irvine, Orange
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- The Center for Cancer Prevention and Treatment at St.Joseph Hospital of Orange, Orange
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- University of California Irvine, Orange
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Ap rekriteFaz 3
- Providence St. Joseph Hospital, Orange
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Ap rekriteFaz 3
- Research Site, Orange
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Ap rekriteFaz 1
- UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange
Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
Ap rekriteFaz 1/2
- Chao Family Comprehensive Cancer Center University of California, Irvine, Orange
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- Research Site, Orange
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Ap rekriteFaz 3
- UCI Chao Family Comprehensive Cancer Center, Orange
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Ap rekriteFaz 1/2
- UC Irvine/Chao Family Comprehensive Cancer Center, Orange
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
Ap rekriteFaz 1
- Research Site, Orange
A Study of VET3-TGI in Patients With Solid Tumors
Ap rekriteFaz 1
- UC Irvine Health, Orange
Assess Diversity of Gut Microbiome in Met NSCLC in Correlation to Tx & Adverse Effects
Ap rekriteEtid obsèvasyon
- Chao Family Comprehensive Cancer Center University of California, Irvine, Orange
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Orange
Etid Kansè Poumon ki pa ti selil nan lòt vil
- Houston, TX145 etid
- New York City, NY121 etid
- Arlington, VA104 etid
- Nashville, TN97 etid
- Boston, MA90 etid
- Los Angeles, CA87 etid
- St. Louis, MO73 etid
- Chicago, IL61 etid
- Baltimore, MD60 etid
- San Antonio, TX59 etid
- Columbus, OH57 etid
- Washington, DC55 etid
Lòt etid nan Orange
- Kansè Metastatik20 etid
- Kansè kolorektal16 etid
- Kansè ovè16 etid
- Kansè pankreyas15 etid
- Melanom14 etid
- Kansè fwa (Kasinòm epatoselilè)14 etid
- Kansè nan tete14 etid
- Kansè poumon14 etid
- Kansè pwostat14 etid
- Kansè lestomak13 etid
- Kansè (tout kalite)13 etid
- Leksemi mieloïd egi13 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.